** Shares of drug developer Elevai Labs decline 14% to 2 cents before the bell
** Late on Friday, ELAB said it will implement a 1-for-200 reverse stock split
** ELAB says stock split will be effective at midnight on Nov. 27 and is intended to bring the company into compliance with Nasdaq's minimum bid price listing rule
** Separately, co also withdraws offer to exchange 15 mln common shares with Series B preferred stock due to logistical issues
** Says will assess whether to commence a new exchange offer
** As of last close, ELAB stock had nearly halved in value so far this year
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。